Bectas Therapeutics was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT).
These funds will support the pre-clinical development of Bectas’ first-in-class precision antibody and patient selection biomarker that together are designed to overcome resistance to existing cancer treatments for over 200,000 patients per year.
Bectas received the top score amongst their cohort of applicants following rigorous diligence review of Bectas science, business and intellectual property, providing independent confirmation of the value we are creating for cancer patients and our investors